Is lysate-based human leukocyte antigen crossmatch a reliable method to contraindicate a transplant?
The presence of preformed cytotoxic donor-specific antibodies (DSAs) has been associated with inferior allograft outcomes in the immediate posttransplant period.Since the 1970s, the primary method for determining the presence of DSAs has been the complement-dependent cytotoxicity crossmatch.Solid phase assays on the Luminex platform were introduced